Aspirin News and Research

RSS

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Longer looks: Making Romneycare work for other states; primary care's new challenge; Boston Marathon first responders continuing battle

Every week reporter Ankita Rao selects interesting reading from around the Web.

18 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

Researchers discover how aspirin improves survival in patients diagnosed with colon cancer

Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer, the 2013 European Cancer Congress (ECC2013) heard today.

1 Oct 2013

Researchers discover how aspirin improves survival in patients with colon cancer

Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer, the 2013 European Cancer Congress heard today (Monday).

30 Sep 2013

Minimally invasive treatments for lumbar spinal stenosis: an interview with James Corbett, President & Chief Executive Officer of Vertos Medical

Lumbar spinal stenosis (LSS) is a degenerative, age-related narrowing of the lower spinal canal that causes pressure on the nerves, leading to pain and reduced mobility. Symptoms include pain, numbness, or tingling in the lower back, legs, or buttocks, which limits your ability to stand or walk.

30 Sep 2013

Anti-inflammatory drug ibuprofen may fight against certain cancers

Latest research by scientists at the University of Bath has shown why the anti-inflammatory drug ibuprofen might stop certain cancers from developing.

26 Sep 2013

Ohio State's Heart and Vascular Center names Garret FitzGerald as recipient of Schottenstein Prize

The Ohio State University Wexner Medical Center's Heart and Vascular Center has named Dr. Garret FitzGerald, professor of Medicine and Pharmacology; chair of the Department of Pharmacology and director of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine at University of Pennsylvania, the recipient of the 2013 Jay and Jeanie Schottenstein Prize in Cardiovascular Sciences.

26 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

P4P incentives in EHR lead to improvements in CV care processes, outcomes

A pay-for-performance program in electronic-health-records-(EHR)-enabled small practices led to modest improvements in cardiovascular care processes and outcomes, according to a study in the September 11 issue of JAMA.

11 Sep 2013

'Pay for performance' programs focus on high quality care delivery

Paying doctors for how they perform specific medical procedures and examinations yields better health outcomes than the traditional "fee for service" model, where everyone gets paid a set amount regardless of quality or patient outcomes, according to new research conducted by UC San Francisco and the New York City Department of Health and Mental Hygiene.

11 Sep 2013

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

...

6 Sep 2013

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

...

5 Sep 2013

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

A shortened pre-surgical interruption of anti-thrombotic therapy, compared to the more traditional one-week interruption, has no influence on perioperative complications in cardiac patients, according to the results of the PRAGUE 14 trial.

5 Sep 2013

Scientists develop new form of aspirin to cope with resistance

Scientists are reporting development of a new form of aspirin - taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke - that could extend aspirin's benefits to people who may not respond to the drug. Their advance toward coping with "aspirin resistance" appears in the journal ACS Nano.

5 Sep 2013

People with CVD more likely to take preventive medicines when combined in one pill

People are much more likely to take preventive medicines if they're combined in one pill, an international study has found. The findings are published today in the Journal of the American Medical Association.

5 Sep 2013

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Aspirin News and Research

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Longer looks: Making Romneycare work for other states; primary care's new challenge; Boston Marathon first responders continuing battle

NAC amino acid may offer new treatment options for psychiatric disorders

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Researchers discover how aspirin improves survival in patients diagnosed with colon cancer

Researchers discover how aspirin improves survival in patients with colon cancer

Minimally invasive treatments for lumbar spinal stenosis: an interview with James Corbett, President & Chief Executive Officer of Vertos Medical

Anti-inflammatory drug ibuprofen may fight against certain cancers

Ohio State's Heart and Vascular Center names Garret FitzGerald as recipient of Schottenstein Prize

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

P4P incentives in EHR lead to improvements in CV care processes, outcomes

'Pay for performance' programs focus on high quality care delivery

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

Scientists develop new form of aspirin to cope with resistance

People with CVD more likely to take preventive medicines when combined in one pill

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Study: Fixed-dose combination medication helps CVD patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News